
Fate Therapeutics FATE
$ 1.91
0.26%
Quarterly report 2026-Q1
added 05-13-2026
Fate Therapeutics Depreciation & Amortization 2011-2026 | FATE
Annual Depreciation & Amortization Fate Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.9 M | 19 M | 18.3 M | 13.8 M | 5.85 M | 3.09 M | 2.19 M | 1.2 M | 971 K | 881 K | 687 K | 496 K | 571 K | 590 K | 672 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19 M | 496 K | 5.41 M |
Quarterly Depreciation & Amortization Fate Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.92 M | - | - | 3.33 M | - | - | - | 4.82 M | - | - | - | 4.19 M | - | 8.92 M | - | 2.76 M | - | 3.64 M | - | 959 K | - | 2.23 M | 1.45 M | 705 K | - | 1.57 M | 983 K | 440 K | - | 877 K | 567 K | 286 K | - | 681 K | 437 K | 206 K | - | 678 K | 460 K | 227 K | - | 477 K | 290 K | 128 K | - | 371 K | 256 K | 123 K | - | 442 K | 302 K | 157 K | - | 430 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.92 M | 123 K | 1.4 M |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Coherus BioSciences
CHRS
|
1.3 M | $ 1.37 | -3.17 % | $ 160 M | ||
|
Happiness Biotech Group Limited
HAPP
|
380 K | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
2.1 M | - | - | $ 2.18 B | ||
|
Alpine Immune Sciences
ALPN
|
576 K | - | - | $ 2.17 B | ||
|
AstraZeneca PLC
AZN
|
5.73 B | - | - | $ 96.9 B | ||
|
Athira Pharma
ATHA
|
972 K | - | - | $ 269 M | ||
|
Galera Therapeutics
GRTX
|
20 K | - | -32.59 % | $ 7.61 M | ||
|
CRISPR Therapeutics AG
CRSP
|
19.5 M | $ 49.84 | -3.19 % | $ 4.48 B | ||
|
Checkmate Pharmaceuticals
CMPI
|
66 K | - | - | $ 231 M | ||
|
Berkeley Lights
BLI
|
9 M | - | -7.31 % | $ 87 M | ||
|
Celldex Therapeutics
CLDX
|
3.38 M | $ 29.36 | -0.81 % | $ 1.95 B | ||
|
Generation Bio Co.
GBIO
|
4.93 M | - | - | $ 344 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
5 K | - | -4.36 % | $ 27 M | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
1.74 M | - | - | $ 384 M | ||
|
Gracell Biotechnologies
GRCL
|
58.8 M | - | - | $ 3.37 B | ||
|
Anika Therapeutics
ANIK
|
5.37 M | $ 14.91 | 2.33 % | $ 214 M | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 2.9 | -2.03 % | $ 4.77 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | ||
|
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
7.72 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
700 K | $ 23.33 | 2.37 % | $ 2.97 B | ||
|
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K |